Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
34 Results for "
USP1
" in MedChemExpress (MCE) Product Catalog:
Products (34)
34 Results for "USP1" in MCE Product Catalog:
17
17 Publications Verification
Cat. No.: HY-17543
CAS No.: 1572414-83-5
Target:
Research Areas:
ML-323 is a reversible, potent USP1-UAF1 inhibitor with IC50 of 76 nM in a Ub-Rho assay. The measured inhibition constants of ML-323 for the free enzyme (Ki) is 68 nM.
14
Category:
Cardiovascular Disease other families Animals Plants Compositae Endogenous metabolite Disease Research Fields Canavalia gladiata (Jacq.) DC. Steroids
Target:
13
13 Cited Publications
Cat. No.: HY-80012
CAS No.: 2070015-29-9
Target:
Research Areas:
SJB3-019A is a potent and novel USP1 inhibitor, 5 times more potent than SJB2-043 in promoting ID1 degradation and cytoxicity in K562 cells with IC50 of 0.0781 μM.
4
4 Cited Publications
Target:
Research Areas:
SJB2-043 is an inhibitor of the native USP1/UAF1 complex with IC50 of 544 nM.
1
Target:
Research Areas:
KSQ-4279 (USP1-IN-1) is a potent USP1 inhibitor and a selective PARP1 inhibitor. KSQ-4279 is promising for research of cancers [1].
1
1 Cited Publications
Target:
Research Areas:
C527 is a is a pan DUB enzyme inhibitor, with a high potency for the USP1/UAF1 complex (IC50=0.88 μM).
1
1 Cited Publications
Cat. No.: HY-145471A
CAS No.: 2938991-80-9
Target:
Research Areas:
KSQ-4279 (gentisate) (Compound Formula I) is a potent USP1 inhibitor and a selective PARP1 inhibitor. KSQ-4279 (gentisate) is promising for research of cancers [1].
Cat. No.: HY-160700
CAS No.: 2839740-79-1
Target:
Research Areas:
TNG348 is an orally available allosteric inhibitor of the ubiquitin-specific protease USP1. TNG348 specifically and efficiently inhibits the activity of USP1, inhibiting its deubiquitination of proliferative PCNA and FANCD2, thereby disrupting the DNA repair process. TNG348 has inhibitory activity against breast and ovarian cancers carrying BRCA1/2 mutations and other homologous recombination defects (HRD) [1] .
Target:
Research Areas:
USP1-IN-3 is a selective USPI inhibitor. USP1-IN-3 inhibits USPI-UAFI with an IC50 value of ＜30 nM. USP1-IN-3 can be used for the research of cancer [1].
Target:
Research Areas:
USP1-IN-2 (Compound I-193) is a potent ubiquitin-specific protease 1 (USP1) inhibitor with an IC50 of less than about 50 nM. USP1-IN-2 can be used for the study of cancers such as osteosarcoma [1].
Target:
Research Areas:
I-138 is an orally active, reversible inhibitor of USP1-UAF1 (IC50: 4.1 nM; Ki: 5.4 nM), structurally related to ML323 (HY-17543). I-138 induces monoubiquitination of FANCD2 and PCNA in cells and eliminates USP1 autocleavage in cells [1].
Cat. No.: HY-153731
CAS No.: 2878441-72-4
Target:
Research Areas:
USP1-IN-4 (compound 10) is an effective USP1 inhibitor with an IC50 value of 2.44 nM. USP1-IN-4 has anticancer activity and synergistic activity with various anticancer drugs [1].
Cat. No.: HY-176704
CAS No.: 2974433-50-4
Target:
Research Areas:
USP1-IN-13 (Compound 2) is a potent and orally active USP1 inhibitor with an IC50 value of 1.02 nM. USP1-IN-13 can be used for the study of breast cancer [1].
Cat. No.: HY-179292
CAS No.: 3084277-96-0
Target:
Research Areas:
USP1-IN-14 (compound 27) is a ubiquitin-specific protease 1 (USP1) inhibitor with an IC50 of 0.001 µM. USP1-IN-14 can be used for USP1-related cancers, autoimmune and inflammatory disorders research [1].
Cat. No.: HY-RS15520
Target:
Research Areas:
USP1 Human Pre-designed siRNA Set A contains three designed siRNAs for USP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-161878
CAS No.: 2857051-98-8
Target:
Research Areas:
USP1-IN-10 (compound 2) is a potent tricyclic USP1 inhibitor with an IC50 of 7.6 nM. USP1-IN-10 inhibits MDA-MB-436 viability (IC50=21.58 nM). USP1-IN-10 has the potential for cancers research [1].
Cat. No.: HY-162633
CAS No.: 2925548-22-5
Target:
Research Areas:
USP1-IN-9 (Compound 1m) is reversible and noncompetitive ubiquitin-specific proteases (USP1) inhibitors with an IC50 of 8.8 nM, which is designed and synthesized to pyrido[2,3-d]pyrimidin-7(8H)-one derivative based on the disclosed structure of ML323(HY-17543) and KSQ-4279(HY-145471). USP1-IN-9 displays excellent USP1/UAF inhibition and exhibits strong antiproliferation effect in breast cancer cells. USP1-IN-9 can generate enhanced cell killing with PARP inhibitor olaparib(HY-10162) in olaparib-resistant MDA-MB-436/OP cells, which is promising for research in the field of cancer [1].
Cat. No.: HY-157558
Synonyms: 8SGE
Target:
Research Areas:
KDRLKZ-1 (8SGE) is a small-molecule ligand of KLHDC2 E3 ligase (Kd = 0.36 μM), with an IC50 of 0.21 μM and 0.31 μM in alphaLISA and TR-FRET assays, respectively. KDRLKZ-1 binds to the substrate-binding pocket of the KLHDC2 kelch domain, mimics the interaction of natural substrates and displaces them. KDRLKZ-1 acts as an oligomer disruptor, regulates the oligomerization of the KLHDC2-EloB-EloC complex, and induces the dissociation of tetramers into smaller components. KDRLKZ-1 can be used in scaffold ligand research for PROTAC degraders targeting KLHDC2 [1].
Cat. No.: HY-RS16567
Target:
Research Areas:
Usp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Usp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
